AbbVie Inc. 2024 Q3 10-Q Filing Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2024. AbbVie Inc. is a global biopharmaceutical company operating as a single global business segment. Key strategic developments during the period included the completion of the ImmunoGen acquisition (February 12, 2024) and the Cerevel Therapeutics acquisition (August 1, 2024). Additionally, Robert A. Michael succeeded Richard A. Gonzalez as CEO on July 1, 2024.
Key Financial Metrics
| Metric (in millions) | Q3 2024 | Q3 2023 | 9M 2024 | 9M 2023 |
|---|---|---|---|---|
| Net Revenues | $14,460 | $13,927 | $41,232 | $40,017 |
| Operating Earnings | $3,831 | $2,281 | $10,627 | $9,562 |
| Net Earnings (Attributable to AbbVie) | $1,561 | $1,778 | $4,300 | $4,041 |
| Diluted EPS | $0.88 | $1.00 | $2.41 | $2.26 |
| Operating Cash Flow (9M) | $11,758 | $18,086 | ||
| Free Cash Flow (9M) | $11,075 | $17,514 | ||
| Total Debt (Current + Long-term) | $71,079 | $59,385 | ||
| Cash and Equivalents | $7,257 | $12,814 | ||
Note: Free Cash Flow calculated as Operating Cash Flow less Capital Expenditures ($683M for 9M 2024, $572M for 9M 2023).
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 3.8% in Q3 and 3.0% for the nine months ended September 30, 2024, compared to the prior year. On a constant currency basis, growth was 4.9% (Q3) and 4.1% (9M).
- Product Performance:
- Humira: Sales declined 37% (Q3) and 34% (9M) due to biosimilar competition following loss of exclusivity.
- Skyrizi: Sales grew 51% (Q3) and 48% (9M), driven by market share uptake.
- Rinvoq: Sales grew 45% (Q3) and 52% (9M), driven by market share uptake and new indications.
- Elahere: Contributed $139M in Q3 and $331M in 9M following the ImmunoGen acquisition.
- Expenses:
- Acquired IPR&D: Increased significantly to $1.183 billion for the nine months ended September 30, 2024 (vs. $496 million in 2023), primarily due to upfront charges for ImmunoGen and Cerevel Therapeutics.
- Other Expense (Income): Included a $3.5 billion charge for the change in fair value of contingent consideration liabilities for the nine months ended September 30, 2024.
- Interest Expense: Increased due to incremental debt issued to finance the ImmunoGen and Cerevel Therapeutics acquisitions.
- Balance Sheet: Total debt increased to $71.1 billion from $59.4 billion at year-end 2023, reflecting $15 billion in new senior notes issued to fund acquisitions. Cash and equivalents decreased to $7.3 billion from $12.8 billion.
Guidance, Outlook, and Risks
- Dividends: The Board declared a quarterly dividend of $1.55 per share for Q3 2024. On October 30, 2024, the Board increased the quarterly dividend to $1.64 per share (a 5.8% increase), effective for the dividend payable in February 2025.
- Share Repurchases: AbbVie repurchased 5 million shares for $959 million during the nine months ended September 30, 2024. Approximately $3.9 billion remains available under the current repurchase authorization.
- Acquisition Outlook: Subsequent to the reporting period, AbbVie announced a definitive agreement to acquire Aliada Therapeutics for an upfront cash payment of approximately $1.4 billion.
- Risks and Contingencies:
- Legal Proceedings: Significant litigation includes antitrust claims (Niaspan, AndroGel), opioid litigation (Allergan), and product liability claims (Biocell breast implants). The recorded accrual for litigation was approximately $2.4 billion as of September 30, 2024.
- Tax Examination: A U.S. federal income tax examination was substantially completed subsequent to the quarter-end. Final resolution is expected in Q4 2024 and may result in a material income tax benefit.
- Patent Expirations: Continued erosion of Humira sales due to biosimilar competition remains a key risk.
Key Facts for Investor Verification
- Acquisition Integration: Verify the progress of integrating ImmunoGen and Cerevel Therapeutics, specifically regarding the realization of synergies and the impact of acquisition-related costs on future earnings.
- Contingent Consideration: Monitor the fair value adjustments of contingent consideration liabilities, which caused a $3.5 billion non-cash charge in the first nine months of 2024 and significantly impacted net earnings.
- Debt Servicing: Assess the impact of the increased debt load ($15 billion new issuance) on interest expenses and liquidity, particularly given the higher interest rate environment.
- Humira Decline vs. New Growth: Track the rate of Humira revenue decline against the growth trajectory of Skyrizi and Rinvoq to ensure the portfolio transition remains on track.
- Legal Accruals: Review updates on the $2.4 billion litigation accrual, particularly regarding the opioid and breast implant litigation, for potential changes in estimated losses.